Erratum: Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial (The Lancet (2010) 376(9753) (1647–1657) (S0140673610619241) (10.1016/S0140-6736(10)61924-1))

Dondorp AM, Fanello CI, Hendriksen ICE, et al, for the AQUAMAT group. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376: 1647–57—In this Article (Nov 13), the row in table 2 for death or sequelae at 28 days in the quinine group should have been: 316/2695 (11·7%). In table 1, the data in parentheses for coma depth are IQR. The last line of the legend for figure 3 should have read: “I² denotes the percentage of total variation across subgroups resulting from heterogeneity rather than chance, with the p value of significance”. The title of figure 5 should have read: “Meta-analysis of all randomised controlled trials that have compared mortality of severe malaria in patients treated with parenteral artesunate versus parenteral quinine^12–16”. These corrections have been made to the online version as of Jan 7, 2011.